STTK - Shattuck Labs, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$12.75
DETAILS
HIGH:
$18.00
LOW:
$7.00
MEDIAN:
$13.00
CONSENSUS:
$12.75
UPSIDE:
158.10%
About Shattuck Labs, Inc. (https://www.shattucklabs.com)
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Taylor H. Schreiber | Co-Founder, Chief Executive Officer & Director | 1980 | $876,232 USD |
| Arundathy Nirmalini Pandite | Chief Medical Officer | 1959 | $734,899 USD |
| Andrew R. Neill | Chief Financial Officer | 1986 | $678,207 USD |
| Abhinav A. Shukla | Chief Technical Officer | 1973 | $567,398 USD |
| Casi DeYoung | Chief Business Officer | 1971 | $523,482 USD |
| Brad Huckabee | Vice President of Accounting & SEC reporting | – | – |
| Kelli Collin | Senior Vice President of Quality | – | – |
| Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | 1975 | – |
| Suresh de Silva | Chief Scientific Officer | – | – |
| Thomas Lampkin | Senior Vice President of Regulatory Affairs | – | – |